Mulhall John P, Valenzuela Rolando, Aviv Nadid, Parker Marilyn
Department of Urology, Cornell University Weill Medical College, New York Presbyterian Hospital, New York, New York 10021, USA.
Urology. 2004 Feb;63(2):348-52; discussion 352-3. doi: 10.1016/j.urology.2003.09.074.
To evaluate the impact of normalization of testosterone levels in men with documented hypogonadism and erectile dysfunction on erectile function and sexual satisfaction. Although the data support the role of testosterone in the preservation of libido and nocturnal erectile function, the evidence supporting the use of testosterone supplementation in hypogonadal men with erectile dysfunction is weak.
This analysis used two validated questionnaires, the International Index of Erectile Function and the Erectile Dysfunction Inventory of Treatment Satisfaction, in a serial fashion at baseline (before treatment) and 1, 3, and 6 months after the achievement of a therapeutic testosterone level.
A total of 32 men met all inclusion criteria; 69% of men achieved therapeutic testosterone levels using transdermal testosterone gel, 19% required a transdermal patch, and 12% required intramuscular delivery. Statistical significance was reached for the difference between the baseline and 1-month International Index of Erectile Function erectile function domain score and all post-treatment International Index of Erectile Function libido scores. A steady decrease occurred in the Erectile Dysfunction Inventory of Treatment Satisfaction scores from the 1 to 6-month values that reached statistical significance.
In men with documented hypogonadism and erectile dysfunction, normalization of serum testosterone levels was associated with only short-term improvement in erectile function and sexual satisfaction. The use of testosterone supplementation in this population for the treatment of erectile dysfunction is questionable.
评估性腺功能减退且有勃起功能障碍的男性睾酮水平正常化对勃起功能和性满意度的影响。尽管数据支持睾酮在维持性欲和夜间勃起功能方面的作用,但支持在性腺功能减退的勃起功能障碍男性中使用睾酮补充治疗的证据不足。
本分析采用两份经过验证的问卷,即国际勃起功能指数和治疗满意度勃起功能障碍量表,在基线(治疗前)以及达到治疗性睾酮水平后的1、3和6个月进行连续评估。
共有32名男性符合所有纳入标准;69%的男性使用经皮睾酮凝胶达到治疗性睾酮水平,19%需要经皮贴片,12%需要肌肉注射。基线与1个月时的国际勃起功能指数勃起功能领域评分以及所有治疗后的国际勃起功能指数性欲评分之间的差异具有统计学意义。治疗满意度勃起功能障碍量表评分从1个月到6个月持续下降,差异具有统计学意义。
在性腺功能减退且有勃起功能障碍的男性中,血清睾酮水平正常化仅与勃起功能和性满意度的短期改善相关。在该人群中使用睾酮补充治疗勃起功能障碍存在疑问。